BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05623345 (Izokibep in Psoriatic Arthritis): BVCT ex-ante prediction vs. reported outcome

On 20 Nov 2023, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 11 Mar 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially insufficient.

Clinical Trial

NCTID
NCT05623345
Drug Name
Izokibep
Drug MoA
IL-17A Inhibitor
Drug Modality
small protein scaffold-based biologic
Drug Class
Best-In-Class
Therapeutic Area
Musculoskeletal Diseases
Indication
Psoriatic Arthritis
Human Patients
351
Sponsor
Acelyrin
Phase
Phase 2 Phase 3

Prediction of , index 1185

Prospective Prediction
Prediction Index
1185
Prediction Date
Commercial Prediction
partial SUCCESS (commercially insufficient clinical benefit with non-superior-to-bimekizumab efficacy and inferior-to-bimekizumab toxicity)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
112 days in advance
Readout Data Interpretation
28% placebo-controlled ACR50 response at wk 16 with 2.5% discontinuation rate; which is inferior to 36% placebo-controlled ACR50 response at wk 16 and 0.4% discontinuation rate; achieved by bimekizumab (DOI- 10.1016/S0140-6736(22)02303-0).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis
Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
351
Lead sponsor
ACELYRIN Inc.
Conditions
Psoriatic Arthritis
Interventions
DRUG: Izokibep; DRUG: Placebo to izokibep
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2022-11-21
Primary completion
2023-11-30
Completion
2024-08-08
Results first posted
2025-05-23
Primary outcomes
  • Number of Participants Who Achieved 50% Improvement in American College of Rheumatology (ACR50) at Week 16 (Week 16)

NCT05623345 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials